Baltimore, MD (PRWEB) February 29, 2012
SNBL CPC one of the nation’s premier and leading providers of early clinical research services is pleased to announce new executive leadership with the arrival of Jerzy J. (George) Debski, RPH as Vice President (VP) of Business Development. As the new VP, Mr. Debski will have overall responsibility for the company’s marketing, sales and business development efforts and will be tasked with driving the growth of SNBL CPC’s business model and fostering positive relationships with new and current customers.
Mr. Patrick R. Ayd COO of SNBL CPC stated, “We wanted to appoint someone that will focus solely on business development and fostering client relations. George has done this with several companies and is a perfect fit”
Mr. Debski joins SNBL CPC with extensive experience in managing national and international Business Development organizations. He has over 30 years of experience with companies including Boehringer Ingelheim, Smith Kline Beecham, Centocor , Pharma Bio-Research, Allied Research International, Veeda and others. Mr. Debski is an accomplished executive with extensive expertise in management, business development, and marketing. His knowledge of the clinical research market place and experiences from the pharmaceutical and contract research organization industries will be of significant value to SNBL CPC and all its customers.
“We wanted to appoint someone that will focus solely on business development and fostering client relations. George has done this with several companies and is a perfect fit,” said Mr. Patrick R. Ayd, COO SNBL CPC. “As an experienced and seasoned industry executive, George’s proven leadership skills will be invaluable as we plan for the coming years and continue to refine and execute our strategy.”
About SNBL Clinical Pharmacology Center:
SNBL CPC is a 96 bed full service Clinical Pharmacology Research facility based in Baltimore, Maryland. Our team is focused on performing high complexity early phase clinical research programs. We conduct clinical trials for multiple segments of clients, including, pharmaceutical, biotech, academic, and government. In addition, SNBL CPC offers all ancillary trial support services such as protocol consulting and design, data management, etc. for early phase I-IIa studies. SNBL’s focus is on First In-Human, Dose Escalation, SAD, MAD, Food Effect, Novel Delivery, Adaptive design, and Infectious Disease challenge studies sets us apart from the vast majority of Early Phase inpatient clinical research facilities. SNBL CPC is pleased to offer our new, state of the art clinical safety laboratory that performs all of the standard safety analyses and moderate to high complexity test procedures.
For further information about SNBL CPC or having our team mange your early phase clinical development program, please contact our client service team at firstname.lastname@example.org or visit our website at http://www.snbl-cpc.com.
+1 (410) 706 8894